My previous research role involved a mixture of application and methodology that typifies the work of the Biostatistics Unit: Monitoring and analyse data from clinical trials, where the aim of these trials was to evaluate the efficacy of antibiotics in treating chronic obstructive pulmonary disease. From these trials, opportunities arose to improve the analysis of the data through novel methodology, or through novel application of existing methodology. Examples include improving treatment effect estimates when data are episodic by taking into account periods when an episode is in progress; analysing drug resistance in bacteria as a continuous, rather than dichotomous, variable, and applying informative censoring methodology to time to event data. I am currently undertaking a PhD in the Unit, working with Adrian Mander and Michael Grayling. The aim to to investigate improvements to single- and two-arm phase II clinical trials with binary outcomes, as well as multi-outcome multi-stage trials with continuous outcomes. I have presented this work at conferences for SCT, ISCB and ICTMC.